OncoMatch/Clinical Trials/NCT07101744
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Is NCT07101744 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Iparomlimab and Tuvonralimab for nasopharyngeal carcinoma (npc).
Treatment: Iparomlimab and Tuvonralimab — This study aims to preliminarily explore the efficacy and safety of Iparomlimab and Tuvonralimab in combination with Nimotuzumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC). It is expected to investigate a novel therapeutic regimen with improved efficacy and enhanced safety for recurrent/metastatic NPC, thereby providing robust evidence-based medical support for the application of dual-target immune checkpoint inhibitors in nasopharyngeal carcinoma therapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy (cisplatin) — first-line
Lab requirements
Blood counts
ANC ≥ 2.0 × 10^9/L, hemoglobin ≥ 9.0 g/dL, platelets ≥ 100 × 10^9/L
Kidney function
Serum creatinine < 1.5 × ULN
Liver function
Total bilirubin < 1.5 × ULN, ALT and AST < 1.5 × ULN
Cardiac function
No significant impairment of cardiac function
Laboratory test results within 7 days prior to enrollment meeting the following criteria: Hematology: Absolute neutrophil count (ANC) ≥ 2.0 × 10^9/L, hemoglobin (Hb) ≥ 9.0 g/dL, platelets (PLT) ≥ 100 × 10^9/L; Liver function: Total bilirubin < 1.5 × ULN, ALT and AST < 1.5 × ULN; Renal function: Serum creatinine < 1.5 × ULN. Significant impairment of cardiac, hepatic, pulmonary, renal, or bone marrow function [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify